/CGC
CGC Stock - Canopy Growth Corporation
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$1.48-12.43%
$0.21 (-12.43%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.34
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+877.7%upside
Target: $14.47
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CGC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.47 – $1.49
TARGET (TP)$14.47
STOP LOSS$1.36
RISK/REWARD1:108.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.14
52W High$3.07
52W Low$0.77
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $269.00M | $297.15M | $333.25M | $475.70M | $546.65M |
| Gross Profit | $79.51M | $80.88M | $-63,529,000 | $-187,414,000 | $66.96M |
| Gross Margin | 29.6% | 27.2% | -19.1% | -39.4% | 12.2% |
| Operating Income | $-117,143,000 | $-228,714,000 | $-2,630,514,000 | $-1,018,799,000 | $-1,243,456,000 |
| Net Income | $-598,115,000 | $-657,269,000 | $-3,278,158,000 | $-310,043,000 | $-1,744,920,000 |
| Net Margin | -222.4% | -221.2% | -983.7% | -65.2% | -319.2% |
| EPS | $-5.53 | $-6.47 | $-70.70 | $-7.70 | $-4.45 |
Company Overview
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
2
50%
Sell / Underperform
2
50%
Analyst Consensus🔴 Bearish
0 Bullish4 Neutral/Bearish
Price Targets
$2
Average Target
↑ 1.4% Upside
Now
$2
Low
$2
Average
$2
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 10th 2025 | The Benchmark Company | Upgrade | Hold | - |
| April 4th 2023 | Bernstein | Upgrade | Market Perform | - |
| November 2nd 2022 | Bernstein | Initiation | Underperform | $1.5 |
| October 26th 2022 | Canaccord Genuity | Upgrade | Hold | - |
| June 8th 2022 | BMO Capital Markets | Downgrade | Underperform | - |
Earnings History & Surprises
CGCBeat Rate
33%
Last 18 quarters
Avg Surprise
-120.0%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q1 24
-297.8%
$-1.79vs$-0.45
Q2 24
+15.2%
$-0.28vs$-0.33
Q3 24
-19.4%
$-0.37vs$-0.31
Q4 24
-150.0%
$-0.95vs$-0.38
Q1 25
-100.0%
$-0.76vs$-0.38
Q2 25
-840.0%
$-0.94vs$-0.10
Q3 25
+6.7%
$-0.14vs$-0.15
Q4 25
+90.9%
$-0.01vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 28, 2026 | — | — | — | — |
Q1 2026 | Feb 6, 2026 | $-0.03 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.11 | $-0.01 | +90.9% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q2 2025 | May 30, 2025 | $-0.10 | $-0.94 | -840.0% | ✗ MISS |
Q1 2025 | Feb 7, 2025 | $-0.38 | $-0.76 | -100.0% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-0.38 | $-0.95 | -150.0% | ✗ MISS |
Q3 2024 | Aug 9, 2024 | $-0.31 | $-0.37 | -19.4% | ✗ MISS |
Q2 2024 | May 30, 2024 | $-0.33 | $-0.28 | +15.2% | ✓ BEAT |
Q1 2024 | Feb 9, 2024 | $-0.45 | $-1.79 | -297.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-1.20 | $-1.80 | -50.0% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-1.00 | $-0.40 | +60.0% | ✓ BEAT |
Q2 2023 | May 26, 2023 | $-0.15 | $-0.42 | -180.0% | ✗ MISS |
Q1 2023 | Feb 9, 2023 | $-1.30 | $-3.50 | -169.2% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-1.80 | $-2.80 | -55.6% | ✗ MISS |
Q3 2022 | Aug 5, 2022 | $-2.00 | $-7.00 | -250.0% | ✗ MISS |
Q2 2022 | May 27, 2022 | $-2.40 | $-4.20 | -75.0% | ✗ MISS |
Q1 2022 | Feb 9, 2022 | $-2.30 | $-2.20 | +4.3% | ✓ BEAT |
Q4 2021 | Nov 5, 2021 | $-1.40 | $-3.90 | -178.6% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $-1.80 | $-1.30 | +27.8% | ✓ BEAT |
Latest News
Marijuana stocks sell off as Trump signs executive order to reclassify cannabis
📉 NegativeDowjones•Dec 18, 2025, 09:24 PM•Also: , ,
Cannabis stocks selling off as Trump signs rescheduling order
📉 NegativeSeeking Alpha•Dec 18, 2025, 07:21 PM•Also: , ,
U.S. Centers For Medicare & Medicaid Services Administrator Says Millions Of Americans On Medicare To Become Eligible To Receive CBD As Early As April
📈 PositiveBenzinga•Dec 18, 2025, 06:59 PM•Also: , ,
Trump Order Will Direct Maintaining Restrictions On Dangerous Products; Centers For Medicare & Medicaid Services Plans To Allow Beneficiaries To Benefit From Hemp-derived Cbd Products At No Cost; Trump Order Will Not Encourage Use, But Recognizes Potential Both Therapeutic Uses And Risks Like Addiction; Marijuana Will Remain Illegal To Possess Under Federal Law; Trump Order Makes No Changes To Criminal Penalties Or Access For Recreational Use Of Marijuana
➖ NeutralBenzinga•Dec 18, 2025, 06:51 PM•Also: , ,
Trump To Sign Executive Order On Thursday Aiming To Expedite Reclassification Of Marijuana As Schedule III Substance; Trump Order Will Allow More Research Of Medical Marijuana And Cannabidiol; Trump Order Will Help U.s. To Better Understand Risks Associated With Marijuana; There Is Currently Insufficient Evidence Of Marijuana's Medical Uses; Trump Order Will Direct White House To Work With Congress To Improve Access To Hemp-Derived CBD Products
📈 PositiveBenzinga•Dec 18, 2025, 06:49 PM•Also: , ,
'Trump's Marijuana Executive Order Details Leaked Ahead Of Announcement, Including CBD And Hemp Provisions'- Marijuana Moment
📈 PositiveBenzinga•Dec 18, 2025, 05:50 PM•Also: , ,
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
📈 PositiveBenzinga•Dec 18, 2025, 12:21 PM•Also: , ,
'Trump's Marijuana Rescheduling Order Could Include Industry Banking And CBD Medicare Coverage Provisions, Sources Say;'- Marijuana Moment
📈 PositiveBenzinga•Dec 17, 2025, 05:01 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following reports suggesting President Trump will sign an executive order that will reclassify marijuana to a Schedule III drug.
📈 PositiveBenzinga•Dec 17, 2025, 02:38 PM•Also: , ,
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
📈 PositiveBenzinga•Dec 17, 2025, 01:38 PM•Also: , ,
'Trump Expected To Sign An Order Moving To Reclassify Cannabis And Open Up Medical Potential' - NBC News
📈 PositiveBenzinga•Dec 17, 2025, 09:12 AM•Also: , ,
Shares of cannabis-linked stocks are trading higher after President Donald Trump confirmed his administration is strongly considering reclassifying marijuana.
📈 PositiveBenzinga•Dec 16, 2025, 07:17 PM•Also: , ,
Liz Claman Posts On X "ALERT: Word is a @realDonaldTrump executive order to reclassify cannabis/marijuana as less dangerous, less regulated Class III substance
📈 PositiveBenzinga•Dec 15, 2025, 08:48 PM•Also: , ,
President Trump Says Considering Executive Oder To Reclassify Marijuana
➖ NeutralBenzinga•Dec 15, 2025, 08:45 PM•Also: , ,
Canopy Growth Agrees To Acquire MTL Cannabis Valued At Approximately $125M On Fully-Diluted Equity Basis And Approximately $179M On An Enterprise Value Basis
📈 PositiveBenzinga•Dec 15, 2025, 12:09 PM
Shares of cannabis-linked stocks are trading higher following a report suggesting that President Trump is expected to reclassify marijuana as a Schedule III drug.
📈 PositiveBenzinga•Dec 12, 2025, 01:23 PM•Also: , ,
'Nebraska Supreme Court Hears Case Seeking To Overturn Medical Marijuana Law Approved By Voters' - Marijuana Moment
➖ NeutralBenzinga•Dec 4, 2025, 01:59 PM•Also: , ,
Canopy Growth Rolls Out New High-Potency Claybourne Gassers Liquid Diamond Vapes Across Canada
📈 PositiveBenzinga•Dec 4, 2025, 12:06 PM
UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News
📈 PositiveBenzinga•Nov 26, 2025, 05:58 PM•Also: , ,
'Marijuana Banking Bill Is 'On The Back Burner,' As Congressional Lawmakers See No Indication It'll Advance Soon' - Marijuana Moment
📉 NegativeBenzinga•Nov 25, 2025, 03:27 PM•Also: , ,
Frequently Asked Questions about CGC
What is CGC's current stock price?
Canopy Growth Corporation (CGC) is currently trading at $1.48 per share. The stock has moved -12.43% today.
What is the analyst price target for CGC?
The average analyst price target for CGC is $14.47, based on 1 analyst.
What sector is Canopy Growth Corporation in?
Canopy Growth Corporation operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is CGC's market cap?
Canopy Growth Corporation has a market capitalization of $0.35 billion, making it a small-cap company.
Does CGC pay dividends?
No, Canopy Growth Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACB
Aurora Cannabis Inc.
$4.96
Mkt Cap: $0.3B
ACRS
Aclaris Therapeutics, Inc.
$3.14
Mkt Cap: $0.3B
BIOA
BioAge Labs, Inc.
$13.39
Mkt Cap: $0.5B
CABA
Cabaletta Bio, Inc.
$2.39
Mkt Cap: $0.2B
DH
Definitive Healthcare Corp.
$2.54
Mkt Cap: $0.3B
IRWD
Ironwood Pharmaceuticals, Inc.
$3.13
Mkt Cap: $0.5B
LFCR
Lifecore Biomedical, Inc.
$8.04
Mkt Cap: $0.3B
LYEL
Lyell Immunopharma, Inc.
$33.33
Mkt Cap: $0.7B
OMI
Owens & Minor, Inc.
$2.84
Mkt Cap: $0.2B
TKNO
Alpha Teknova, Inc.
$4.65
Mkt Cap: $0.2B
Explore stocks similar to CGC for comparison